Reach Neuro

Reach Neuro is a neurotechnology startup developing spinal cord stimulation devices to restore shoulder, arm, and hand movement for people with chronic stroke and other neurological disorders. The company's Avantis platform — which received FDA Breakthrough Device designation in 2023 — uses implanted electrode arrays and a pulse generator to deliver personalized stimulation protocols that re-awaken the nervous system and directly restore a patient's ability to control their own movement. Co-founded by researchers from Brown University and the University of Pittsburgh, Reach Neuro is backed by SOSV and has demonstrated first-in-human results published in Nature Medicine.